Duopharma Biotech Berhad (KLSE:DPHARMA)
Malaysia flag Malaysia · Delayed Price · Currency is MYR
1.380
+0.010 (0.73%)
At close: Sep 12, 2025

Duopharma Biotech Berhad Statistics

Total Valuation

KLSE:DPHARMA has a market cap or net worth of MYR 1.33 billion. The enterprise value is 1.57 billion.

Market Cap1.33B
Enterprise Value 1.57B

Important Dates

The last earnings date was Friday, August 15, 2025.

Earnings Date Aug 15, 2025
Ex-Dividend Date Sep 8, 2025

Share Statistics

KLSE:DPHARMA has 961.94 million shares outstanding. The number of shares has decreased by -0.06% in one year.

Current Share Class 961.94M
Shares Outstanding 961.94M
Shares Change (YoY) -0.06%
Shares Change (QoQ) n/a
Owned by Insiders (%) 0.30%
Owned by Institutions (%) 72.24%
Float 450.08M

Valuation Ratios

The trailing PE ratio is 17.34 and the forward PE ratio is 14.20. KLSE:DPHARMA's PEG ratio is 0.72.

PE Ratio 17.34
Forward PE 14.20
PS Ratio 1.50
PB Ratio 1.80
P/TBV Ratio 1.92
P/FCF Ratio 13.37
P/OCF Ratio 9.96
PEG Ratio 0.72
Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 9.91, with an EV/FCF ratio of 15.78.

EV / Earnings 20.48
EV / Sales 1.77
EV / EBITDA 9.91
EV / EBIT 13.33
EV / FCF 15.78

Financial Position

The company has a current ratio of 3.98, with a Debt / Equity ratio of 0.67.

Current Ratio 3.98
Quick Ratio 2.65
Debt / Equity 0.67
Debt / EBITDA 3.13
Debt / FCF 4.99
Interest Coverage 4.79

Financial Efficiency

Return on equity (ROE) is 10.70% and return on invested capital (ROIC) is 6.00%.

Return on Equity (ROE) 10.70%
Return on Assets (ROA) 5.32%
Return on Invested Capital (ROIC) 6.00%
Return on Capital Employed (ROCE) 9.60%
Revenue Per Employee 453,205
Profits Per Employee 39,102
Employee Count1,957
Asset Turnover 0.64
Inventory Turnover 2.31

Taxes

In the past 12 months, KLSE:DPHARMA has paid 21.76 million in taxes.

Income Tax 21.76M
Effective Tax Rate 22.14%

Stock Price Statistics

The stock price has increased by +18.97% in the last 52 weeks. The beta is 0.36, so KLSE:DPHARMA's price volatility has been lower than the market average.

Beta (5Y) 0.36
52-Week Price Change +18.97%
50-Day Moving Average 1.35
200-Day Moving Average 1.28
Relative Strength Index (RSI) 58.56
Average Volume (20 Days) 797,835

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, KLSE:DPHARMA had revenue of MYR 886.92 million and earned 76.52 million in profits. Earnings per share was 0.08.

Revenue886.92M
Gross Profit 328.67M
Operating Income 117.56M
Pretax Income 98.28M
Net Income 76.52M
EBITDA 154.62M
EBIT 117.56M
Earnings Per Share (EPS) 0.08
Full Income Statement

Balance Sheet

The company has 255.50 million in cash and 495.12 million in debt, giving a net cash position of -239.62 million or -0.25 per share.

Cash & Cash Equivalents 255.50M
Total Debt 495.12M
Net Cash -239.62M
Net Cash Per Share -0.25
Equity (Book Value) 736.09M
Book Value Per Share 0.77
Working Capital 575.91M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 133.35 million and capital expenditures -34.06 million, giving a free cash flow of 99.29 million.

Operating Cash Flow 133.35M
Capital Expenditures -34.06M
Free Cash Flow 99.29M
FCF Per Share 0.10
Full Cash Flow Statement

Margins

Gross margin is 37.06%, with operating and profit margins of 13.26% and 8.63%.

Gross Margin 37.06%
Operating Margin 13.26%
Pretax Margin 11.08%
Profit Margin 8.63%
EBITDA Margin 17.43%
EBIT Margin 13.26%
FCF Margin 11.19%

Dividends & Yields

This stock pays an annual dividend of 0.03, which amounts to a dividend yield of 2.17%.

Dividend Per Share 0.03
Dividend Yield 2.17%
Dividend Growth (YoY) 25.00%
Years of Dividend Growth 1
Payout Ratio 37.71%
Buyback Yield 0.06%
Shareholder Yield 2.23%
Earnings Yield 5.76%
FCF Yield 7.48%
Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on September 6, 2021. It was a forward split with a ratio of 1.3333333333.

Last Split Date Sep 6, 2021
Split Type Forward
Split Ratio 1.3333333333

Scores

KLSE:DPHARMA has an Altman Z-Score of 2.82 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score 2.82
Piotroski F-Score 7